Post written by: BioTech Health X
You May Also Like
Monopar Therapeutics (MNPR) Strengthens Financial Stability with $17.7M Public Offering
- BioTech Health X
- December 27, 2024
- 4 minute read
Table of Contents Hide Strategic Expansion with ALXN-1840 for Wilson DiseaseAdvancing Radiopharmaceutical InnovationFinancial Strength Supporting Sustained GrowthOperational Efficiency…
Mirum Pharmaceuticals (MIRM) Flexes 46% LIVMARLI Sales Growth
- BioTech Health X
- October 17, 2026
- 3 minute read
Table of Contents Hide Big Growth Numbers Still Need a CheckupA Ranking Built on More Than a Good…
Investors Are Watching XOMA Ahead of 2025’s Major Clinical Readouts
- BioTech Health X
- May 10, 2025
- 5 minute read
Table of Contents Hide A Transformational 2024: Expanding Royalty Revenue and Portfolio ValueStrategic Royalty Acquisitions Drive Future GrowthValue-Driven…
Kura Oncology (KURA) Skyrockets After FDA Approves KOMZIFTI for NPM1-Mutated AML
- BioTech Health X
- November 16, 2025
- 7 minute read
Table of Contents Hide A Critical Look at Kura Oncology (NASDAQ:KURA): Why Fundamental Risks Persist Despite KOMZIFTI ApprovalEfficacy…
Is Thermo Fisher (TMO) a Good Choice for Long-Term Investors?
- BioTech Health X
- August 15, 2026
- 8 minute read
Table of Contents Hide Aging Americans Could Keep Healthcare Demand GrowingGLP-1 Drugs Have Changed the Healthcare Investment StoryArtificial…
Why Krystal Biotech (KRYS) Is Becoming a Name Investors Can’t Ignore
- BioTech Health X
- January 25, 2026
- 7 minute read
Few biotechnology companies manage to transition from bold scientific ambition to real-world therapeutic impact, yet this company was…